ENTITY
Biogen Inc

Biogen Inc (BIIB US)

144
Analysis
Health CareUnited States
Biogen Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products address diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, Crohn's disease, and psoriasis.
more
25 Jul 2017 21:50

Biogen Likes Biosimilars

Biogen Inc (BIIB US) , the partner of Samsung Biologics Co., Ltd (207940 KS) in the Samsung Bioepis JV, reported Q2 2017 results this morning and...

Share
bearishCelltrion Inc
19 Jul 2017 06:14

JNJ's REMICADE Holds: PFE's Results To Confirm

Johnson & Johnson (JNJ US) reported Q2 2017 results today (quotes from earnings call are below). US revenue for REMICADE (reference product for...

Share
11 Mar 2017 06:29

Reconsider the Samsung Bioepis Valuation

As noted in our Insight Pass on the Deal, Put on the Watchlist one of the underpinnings of the valuation of Samsung Biologics Co., Ltd (207940 KS)...

Share
09 Mar 2017 17:09

US Healthcare Overhaul Stumbling, Singapore Cyclical Rally Looking Premature

The Republican replacement for ‘Obamacare’ has been announced and looks an incoherent mess – resurgent healthcare inflation will be a drag on...

Logo
1.6k Views
Share
27 Feb 2017 14:28

AI & Machine Learning Disrupting The Healthcare Industry

In the omnipresence of machine learning, one of the most impacted segments is healthcare. Not only is AI in healthcare at the forefront of a...

Logo
601 Views
Share
x